NCT02476552View on ClinicalTrials.gov

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2018

Conditions
Cancer
Interventions
DRUG

Niraparib Oral Capsules (Labeled)

Single 300 mg dose of niraparib

DRUG

Niraparib IV (Labeled)

Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)

DRUG

Niraparib Oral Capsules (Unlabeled)

Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)

Trial Locations (1)

1066 CX

The Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
lead

Tesaro, Inc.

INDUSTRY

NCT02476552 - Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer | Biotech Hunter | Biotech Hunter